Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 13/20 | 1.00 |
| ▸ | MME | P08473 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29353579 | 1.00 | ECE1 (1.00) | ECE1MMEMEN1KMT2AACE | |
| SCHEMBL7697566 | 1.00 | ECE1 (1.00) | ECE1MMEMEN1KMT2AACE | |
| SCHEMBL13034961 | 0.90 | ECE1 (0.81) | ECE1MMEMEN1KMT2AACE | |
| SCHEMBL4204106 | 0.86 | ECE1 (0.75) | ECE1MMEMEN1KMT2A | |
| SCHEMBL13783411 | 0.82 | ECE1 (0.70) | ECE1MMEMEN1KMT2A | |
| SCHEMBL7973922 | 0.80 | ECE1 (0.67) | ECE1MMEMEN1KMT2A | |
| SCHEMBL43351 | 0.78 | MME (0.62) | ECE1MMEMEN1KMT2AACE | |
| SCHEMBL43350 | 0.78 | MME (0.62) | ECE1MMEMEN1KMT2AACE | |
| SCHEMBL7411127 | 0.77 | MME (0.62) | ECE1MMEMEN1KMT2AACE | |
| SCHEMBL7411123 | 0.77 | MME (0.62) | ECE1MMEMEN1KMT2AACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090311266-A1 | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy | BASF AKTIENGESELLSCHAFT (DE) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090311266-A1 | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy | EDNRB, EDNRA, ITGB3 | ECE1 7/4885MME 436/4885MEN1 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.